Αρχική World News Patients With DCIS Reduce Risk Of Recurrence And Death If They Undergo...

Patients With DCIS Reduce Risk Of Recurrence And Death If They Undergo Immediate Treatment, Study Finds

Ductal carcinoma in situ (DCIS) is also called stage 0 breast cancer or pre-cancer. It means that malignant cancer cells have been found in the milk ducts but have not spread beyond them. It’s considered cancer and is something to take seriously, but the prognosis is typically good and it is treatable.In fact, because of its early stage, there has actually been concern about over-diagnosis and over-treatment of DCIS in the medical community. Do some women with such early-stage cancer really need to get a double mastectomy or undergo radiation? Can some patients instead take a wait-and-see approach to see if the cancer becomes more aggressive?It’s a risk many breast cancer patients are (rightfully) not willing to take. It’s difficult for many people to justify active surveillance instead of immediate treatment when it comes to a cancer diagnosis; there’s a lot of fear of the unknown.A study of DCIS cases in the United Kingdom seems to support the idea that immediate treatment is the best route to go — but other experts are still skeptical.The UK StudyPhoto: Adobe Stock/TsuynaThe study was published online in the British Medical Journal. Researchers from the University of Oxford in the UK analyzed the data of 35,024 women who were diagnosed with DCIS between 1988 and 2014.They found that any diagnosis of DCIS (low, intermediate, or high grade) is linked to an increased risk of invasive breast cancer (IBC) and death. The risk of IBC after a DCIS diagnosis was over double that of national cancer incidence rates, with an incidence rate of 8.82 per 1000 per year. The risk of death was also more than double, with a death rate of 1.26 per 1,000 per year. This is 70% higher than the national rate.Increased risk of invasive breast cancer started two years after the initial diagnosis of DCIS and continued for 20 years.However, immediate treatment seemed to result in a lower risk of IBC. In particular, it was lower for women who had both breast-conserving surgery and radiation, women with ER+ cancer who underwent hormone therapy, and women who had larger surgical margins.Experts DisagreePhoto: Adobe Stock/arcytoSome experts in the medical community who were not associated with the study disagree with the findings, and have pointed out problems with the study’s conclusions.Henry M. Kuerer, MD, is a professor of breast surgical oncology at the University of Texas MD Anderson Cancer Center in Houston. He says that improved treatment methods over the past 30 years overall have led to better outcomes, not immediate and radical treatment.“The conclusion that mastectomy for patients — that is, more radical treatment — might lead to improvement is patently false,” he told Medscape Medical News.The study analyzed DCIS patients as far back as the ’80s, and treatment and detection have both come a long way since then. Kuerer emphasized that health professionals are now able to isolate and treat small amounts of cancerous tissue using more advanced technology, and clear margins are seen in much greater detail.The most notable addition to breast cancer treatment over the past couple decades has been endocrine therapy (commonly referred to as hormone therapy) — and that could be the driving factor in creating better outcomes for DCIS patients.The Role Of Hormone TherapyPhoto: Adobe Stock/Anut21ngDr. Laura Esserman, MD, MBA, is the director of the Carol Franc Buck Breast Care Center at the University of California, San Francisco, and she is a strong proponent for managing most DCIS cases by active surveillance since 95% of DCIS is minimal risk.“It is incumbent upon us to learn how to better manage DCIS across the spectrum of the types of DCIS. It is likely that some women may be very responsive to risk reduction with endocrine therapy alone and may never need surgery, while others may benefit from a surgical removal,” Esserman said.In the UK study, patients who had the highest breast cancer mortality rates or were at the highest risk for getting invasive breast cancer were diagnosed between 1988 and 2000. This is before hormone therapy was used to treat DCIS.“This in fact suggests that the biggest difference can be made with endocrine therapy,” Esserman said.Next StepsPhoto: Adobe Stock/alfa27Vered Stearns, MD, is a professor of oncology, the breast cancer research chair in oncology, and director of the Women’s Malignancies Disease Group at Johns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland.“Clinicians should continue to recommend optimal local treatment to women with DCIS and also discuss the role of endocrine therapy,” Stearns said. “I hope that there will not be a tendency to recommend or choose a mastectomy [after a diagnosis of DCIS].”“Until we have strong biological markers to truly differentiate DCIS or invasive cancer with a high risk of recurrence, invasion, and metastases, I support the use of screening programs in carefully selected patients based on their age, comorbidities, and other characteristics,” she added. “Women should continue to have annual screening mammograms as long as they are in good health and have a reasonable life expectancy.”There are currently several other trials looking at the best treatment options for women with DCIS. We look forward to seeing the results of those.Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...